Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation

被引:24
|
作者
Stenehjem, Jo S. [1 ,2 ]
Smeland, Knut B. [1 ]
Murbraech, Klaus [3 ]
Holte, Harald [4 ]
Kvaloy, Stein [1 ,5 ]
Thorsen, Lene [1 ]
Arbo, Ingerid [6 ]
Jones, Lee W. [7 ]
Aakhus, Svend [3 ,6 ]
Lund, May Brit [8 ]
Kiserud, Cecilie E. [1 ]
机构
[1] Oslo Univ Hosp, Dept Oncol, Natl Resource Ctr Late Effects Canc Treatment, N-0424 Oslo, Norway
[2] Canc Registry Norway, Dept Res, N-0304 Oslo, Norway
[3] Oslo Univ Hosp, Dept Cardiol, N-0424 Oslo, Norway
[4] Oslo Univ Hosp, Dept Oncol, N-0424 Oslo, Norway
[5] Univ Oslo, Fac Med, N-0316 Oslo, Norway
[6] NTNU, Dept Circulat & Med Imaging, N-7491 Trondheim, Norway
[7] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10065 USA
[8] Oslo Univ Hosp, Dept Resp Med, N-0424 Oslo, Norway
关键词
cardiorespiratory fitness; autologous stem cell transplantation; lymphoma survivors; late effects; physical activity; VENTRICULAR SYSTOLIC DYSFUNCTION; BONE-MARROW-TRANSPLANTATION; MAXIMAL AEROBIC CAPACITY; HODGKINS-DISEASE; HEART-FAILURE; CONDITIONAL SURVIVAL; PHYSICAL-ACTIVITY; MULTIPLE-MYELOMA; CHILDHOOD-CANCER; INCREASED RISK;
D O I
10.1038/bjc.2016.180
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Cardiorespiratory fitness as measured by peak oxygen consumption (VO2peak) is a strong predictor of longevity and may be compromised by anticancer therapy, inactivity, and smoking. We compared VO2peak among lymphoma survivors (LSs) with reference data from healthy sedentary subjects, after a 10.2-year (mean) follow-up post high-dose chemotherapy with autologous stem cell transplantation (HDT-ASCT). We further examined the association between VO2peak and treatment, physical activity, smoking, pulmonary, and cardiac function. Methods: Lymphoma survivors treated with HDT-ASCT in Norway 1987-2008 were eligible. VO2peak was assessed by cardiopulmonary exercise testing. Pulmonary function testing and echocardiography were also conducted. Data on treatment, physical activity, and smoking were collected from hospital records and questionnaires. VO2peak was compared with age-sex predicted reference data. Linear regression was used to associate clinical factors with VO2peak cross-sectionally. Results: A total of 194 LSs without heart failure were studied. Mean VO2peak was 4.5% and 7.7% below norms in females and males, respectively. Twenty-two percent had impaired (<80% predicted) VO2peak. Decreasing VO2peak was associated with impaired diffusion capacity and current smoking, while physical activity level and VO2peak were positively associated. Conclusion: We suggest increased attention towards physical activity counseling and smoking cessation advice to preserve cardiorespiratory fitness in LSs after HDT-ASCT. Patients with impaired diffusion capacity may benefit from subsequent monitoring to detect pulmonary vascular diseases.
引用
收藏
页码:178 / 187
页数:10
相关论文
共 50 条
  • [31] Long-Term Results of High-Dose Therapy and Autologous Stem Cell Transplantation for Mantle Cell Lymphoma: Effectiveness of Maintenance Rituximab
    Mei, Matthew G.
    Cao, Thai M.
    Chen, Lu
    Song, Joo Y.
    Siddiqi, Tanya
    Cai, Ji-Lian
    Farol, Leonardo T.
    Al Malki, Monzr M.
    Salhotra, Amandeep
    Aldoss, Ibrahim
    Palmer, Joycelynne
    Herrera, Alex F.
    Zain, Jasmine
    Popplewell, Leslie L.
    Chen, Robert W.
    Rosen, Steven T.
    Forman, Stephen J.
    Kwak, Larry
    Nademanee, Auayporn P.
    Budde, Lihua E.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (11) : 1861 - 1869
  • [32] Scleromyxedema: long-term follow-up after high-dose melphalan with autologous stem cell transplantation
    Chockalingam, Ramya
    Duvic, Madeleine
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2016, 55 (10) : E539 - E543
  • [33] Determinants of cardiorespiratory fitness in young long-term survivors of hematopoietic stem cell transplantation (HSCT)
    Myrdal, Ole Henrik
    Diep, Phoi Phoi
    Ruud, Ellen
    Brinch, Lorentz
    Massey, Richard J.
    Edvardsen, Elisabeth
    Kongerud, Johny
    Sikkeland, Liv Ingunn Bjoner
    Lund, May Brit
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [34] Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis
    Perz, JB
    Rahemtulla, A
    Giles, C
    Szydlo, RM
    Davis, J
    Gopaul, D
    Gillmore, J
    Mathias, CJ
    Hawkins, PN
    Apperley, JF
    BONE MARROW TRANSPLANTATION, 2006, 37 (10) : 937 - 943
  • [35] Long-term outcome of high-dose melphalan and autologous stem cell transplantation for AL amyloidosis
    J B Perz
    A Rahemtulla
    C Giles
    R M Szydlo
    J Davis
    D Gopaul
    J Gillmore
    C J Mathias
    P N Hawkins
    J F Apperley
    Bone Marrow Transplantation, 2006, 37 : 937 - 943
  • [36] Long-term Outcomes in Primary CNS Lymphoma After R-MVP and High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplant
    Therkelsen, Kate Elizabeth
    Schaff, Lauren R.
    Nandakumar, Subhiksha
    Omuro, Antonio M. P.
    DeAngelis, Lisa M.
    Grommes, Christian
    NEUROLOGY, 2023, 101 (07) : E710 - E716
  • [37] Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma
    Pott, C
    Schrader, C
    Gesk, S
    Harder, L
    Tiemann, M
    Raff, T
    Brüggemann, M
    Ritgen, M
    Gahn, B
    Unlerhalt, M
    Dreyling, M
    Hiddemann, W
    Siebert, R
    Dreger, P
    Kneba, M
    BLOOD, 2006, 107 (06) : 2271 - 2278
  • [38] High-dose sequential chemotherapy (HDS) followed by autologous stem cell transplantation (ASCT) in relapsing/refractory Hodgkin lymphoma (HL): Long-term results
    Gallamini, Andrea
    Castellino, Claudia
    Viviani, Simonetta
    Rossi, Andrea
    Billio, Atto
    Mistretta, Alessandro
    Sorio, Marco
    Gueli, Angela
    Rambaldi, Alessandro
    Cortelazzo, Sergio
    Patti, Caterina
    Benedetti, Fabio
    Torchio, PierFederico
    Gianni, Alessandro M.
    Tarella, Corrado
    BLOOD, 2007, 110 (11) : 361B - 361B
  • [39] Progressive disease after high-dose chemotherapy with autologous stem cell transplantation (ASCT) in lymphoma patients.
    Mayer, J
    Vásová, I
    Tomíska, M
    Navrátil, M
    Korístek, Z
    Král, Z
    Vorlícek, J
    BONE MARROW TRANSPLANTATION, 1999, 23 : S75 - S75
  • [40] High-dose sequential chemotherapy (HDS) followed by autologous stem cell transplantation (ASCT) in relapsing/refractory Hodgkin lymphoma (HL): Long-term results
    Gallamini, A.
    Castellino, C.
    Viviani, S.
    Rossi, A.
    Billio, A.
    Mistretta, A.
    Benedetti, F.
    Gavarotti, P.
    Gianni, A.
    Rambaldi, A.
    Crtelazzo, S.
    Patti, C.
    Pizzolo, G.
    Parvis, G.
    Tarella, C.
    ANNALS OF ONCOLOGY, 2008, 19 : 136 - 136